A pH-sensitive binary drug delivery system based on poly(caprolactone)- heparin conjugates

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 3, 2014, Pages 880-889

  Ye, Lin ^a   Gao, Zemin ^a   Zhou, Yu ^a   Yin, Xuan ^a   Zhang, Xinpeng ^a   Zhang, Aiying ^a   Feng, Zengguo ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

binary drug delivery system; doxorubicin; paclitaxel; PCL heparin conjugate; pH sensitive

Indexed keywords

DELIVERY SYSTEMS; DOXORUBICIN; PACLITAXEL; PCL-HEPARIN CONJUGATE; PH SENSITIVE;

CONTROLLED DRUG DELIVERY; DISEASES; NANOPARTICLES; POLYSACCHARIDES; TUMORS;

CYTOLOGY;

DOXORUBICIN; HEPARIN; PACLITAXEL; POLYCAPROLACTONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; LIPOPHILICITY; PARTICLE SIZE; PH; STATIC ELECTRICITY; SUSTAINED DRUG RELEASE; UTERINE CERVIX CANCER;

BINARY-DRUG DELIVERY SYSTEM; DOXORUBICIN; PACLITAXEL; PCL-HEPARIN CONJUGATE; PH SENSITIVE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; FEMALE; HELA CELLS; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; PACLITAXEL; POLYESTERS; UTERINE CERVICAL NEOPLASMS;

EID: 84892574074     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34735     Document Type: Article

References (34)

1. Bae Y, Fukushima S, Harada A, Kataoka K,. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Micelles that are responsive to intracellular pH change. Angew Chem Int Ed 2003; 42: 4640-4643.
2. Sutton D, Nasongkla N, Blanco E, Gao JM,. Functionalized micellar systems for cancer targeted drug delivery. Pharma Res 2007; 24: 1029-1046.
3. Davis ME, Chen Z, Shin DM,. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev 2008; 7: 771-782.
4. Ruoslahti E, Bhatia SN, Sailor MJ,. Targeting of drugs and nanoparticles to tumors. J Cell Bid 2010; 188: 759-768.
5. Kedar U, Phutane P, Shidhaye S, Kadam V,. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotech Biol Med 2010; 6: 714-729.
6. Danhier F, Feron O, Préat VT,. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148: 135-146.
7. Keefe MK, Bateman EH,. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev 2012; 9: 98-109.
8. Beduneau A, Saulnier P, Benoit JP,. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-4967.
9. Malhi SS, Budhiraja A, Arora S, Chaudhari KR, Nepali K, Kumar R, Sohi H, Murthy RSR,. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. Int J Pharm 2012; 432: 63-74.
10. Yoo HS, Park TG,. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004; 96: 273-283.
11. Ding CX, Gu JX, Qu XZ, Yang ZZ,. Preparation of multifunctional drug carrier for tumor-specific uptake and enhanced intracellular delivery through the conjugation of weak acid labile linker. Bioconjugate Chem 2009; 20: 1163-1170.
12. Rapoport N,. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polym Sci 2007; 32: 962-990.
13. Chen W, Meng FH, Cheng R, Zhong ZY,. pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles. J Control Release 2010; 142: 40-46.
14. Zhao LL, Zhu LJ, Liu FY, Liu CY, Dan S, Wang Q, Zhang CL, Li JL, Liu JG, Qua XZ, Yang ZZ,. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel. Int J Pharm 2011; 410: 83-91.
15. Cochran MC, Eisenbrey J, Ouma RO, Soulen M, Wheatley MA,. Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. Int J Pharm 2011; 414: 161-170.
16. Gaucher G, Marchessault RH, Leroux JC,. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010; 143: 2-12.
17. Yang DB, Liu XQ, Jiang XG, Liu Y, Ying WB, Wang H, Bai H, Taylor WD, Wang YW, Clamme JP, Co E, Chivukula P, Tsang KY, Jin Y, Yu L,. Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy. J Control Release 2012; 161: 124-131.
18. Zhan CY, Gu B, Xie C, Li J, Liu Y, Lu WY,. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010; 143: 136-142.
19. Iqbal J, Sarti F, Perera G, Bernkop-Schnürch A,. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 2011; 32: 170-175.
20. Lee JS, Feijen J,. Biodegradable polymersomes as carriers and release systems for paclitaxel using Oregon Green® 488 labeled paclitaxel as a model compound. J Control Release 2012; 158: 312-318.
21. Ye L, Wu X, Mu Q, Chen B, Duan HY, Geng X, Gu YQ, Zhang AY, Zhang J, Feng ZG,. Heparin-conjugated PCL scaffolds fabricated by electrospinning and loaded with fibroblast growth factor 2. J Biomater Sci Polym Ed 2011; 22: 389-406.
22. Ye L, Wu X, Mu Q, Geng X, Duan HY, Chen B, Gu YQ, Zhang AY, Zhang J, Feng ZG,. Initiator-free photocrosslink of electrospun biodegradable polyester tubular scaffold and its cell affinity for vascular tissue engineering. Chin J Polym Sci 2010; 28: 829-840.
23. Geng X, Ye L, Chen B, Wang PJ, Zhang AY, Zhang J, Feng ZG,. Synthesis and characterization of anticoagulant heparinized É-caprolactone/L-lactide copolymers and their electrospinning Study. Chin J Chin Univ 2010; 31: 205-211.
24. Ye L, Wu X, Duan HY, Geng X, Chen B, Gu YQ, Zhang AY, Zhang J, Feng ZG,. The in vitro and in vivo biocompatibility evaluation of heparin-PCL conjugate for vascular tissue engineering scaffolds. J Biomed Mater Res A 2012; 100A: 3251-3258.
25. Wang Y, Xin DC, Liu KJ, Zhu MQ, Xiang JN,. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjugate Chem 2009; 20: 2214-2221.
26. Weitz JI,. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
27. Young E,. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122: 743-752.
28. Hou L, Yao J, Zhou JP, Zhang Q,. Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-transretinoid acid conjugate ternary nanoparticulate drug delivery system. Biomaterials 2012; 33: 5431-5440.
29. Park K, Lee GY, Park RW, Kim IS, Kim SY, Byun Y,. Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. Pharm Res 2008; 25: 268-276.
30. Zhu CZ, Jung SY, Luo SB, Meng FH, Zhu XL, Park TG, Zhong ZY,. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010; 31: 2408-2416.
31. Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu GF, Kneller S, Davies J, Duncan R,. PEG-Doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjugate Chem 2005; 16: 775-784.
32. Wong LJ, Kavallaris M, Bulmus V,. Doxorubicin conjugated, crosslinked, PEGylated particles prepared via one-pot thiol-ene modification of a homopolymer scaffold: synthesis and in vitro evaluation. Polym Chem 2011; 2: 385-393.
33. Duncan R,. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688-701.
34. Kim WJ, Kim SS,. Synthesis of biodegradable triple-layered capsules using a triaxial electrospray method. Polymer 2011; 52: 3325-3336.